ArticleJournal of nanobiotechnology2026
Bioactive eggshell membrane-integrated nanofiber dressing with mesoporous polydopamine-mediated sustained dexamethasone delivery for enhanced wound regeneration.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Wound healing is often impeded by excessive inflammation and oxidative stress, necessitating multifunctional dressings with therapeutic and regenerative properties. Here, a biodegradable nanofiber dressing (PE@MD) composed of poly(L-lactide-co-ε-caprolactone) (PLCL), water-soluble eggshell membrane (ESM), and dexamethasone (DEX)-loaded mesoporous polydopamine nanoparticles (MPDA) was developed via electrospinning technology. Proteomic and metabolomic analyses revealed that ESM contains abundant proteins and metabolites associated with cytoskeletal organization, antioxidation, and modulation of inflammation, providing intrinsic bioactivity to the composite. The incorporation of MPDA enabled sustained and controlled DEX release while enhancing the ROS scavenging capacity. The optimized PE@MD nanofibers exhibited good flexibility, biocompatibility, and degradation properties. In vitro, the dressing promoted the migration of fibroblasts and endothelial cells, reduced ROS levels, and induced macrophage polarization toward the M2 phenotype through NF-κB inhibition. Transcriptomic analysis confirmed activation of antioxidant and extracellular matrix remodeling pathways. The PE@MD significantly accelerated wound closure, re-epithelialization, and collagen deposition while reducing COX-2, IL-1β, MPO, and NF-κB p65 expression in a rat full-thickness wound model. These findings demonstrate that the PE@MD dressing effectively integrates bioactive ESM and MPDA-mediated sustained drug release, providing a sustainable and multifunctional platform that promotes enhanced collagen deposition, accelerated re-epithelialization, and reduced inflammatory infiltration during skin repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.